Virological success (<400 copies/ml) at 12 months–on-treatment analysis.

<p>Virological success (<400 copies/ml) at 12 months–on-treatment analysis.</p

Rate of virological success (<400 copies/ml) at 24 months–on-treatment analysis.

<p>Rate of virological success (<400 copies/ml) at 24 months–on-treatment analysis.</p

Intention-to-treat analysis of the proportion of virological success (400 copies/mL) at 24 months of ART by study design.

<p>Intention-to-treat analysis of the proportion of virological success (400 copies/mL) at 24 months of ART by study design.</p

Flow chart of study selection.

<p>Flow chart of study selection.</p

Rate of virological success (<400 copies/ml) at 12 months–intention to treat analysis.

<p>Rate of virological success (<400 copies/ml) at 12 months–intention to treat analysis.</p

On treatment analysis of the proportion of virological success (400 copies/mL) at 12 months of ART by study design.

<p>On treatment analysis of the proportion of virological success (400 copies/mL) at 12 months of ART by study design.</p

Checklist of items retained from the STROBE statement.

<p>Checklist of items retained from the STROBE statement.</p

Characteristics of the studies presenting incidence rate of switching to second-line ART.

<p>Characteristics of the studies presenting incidence rate of switching to second-line ART.</p

Multivariate analysis of factors associated with the occurrence of Q151M and K65R mutations.

†<p>Odd ratio estimated using logistic analysis.</p>‡<p>95% Confident interval.</p

Flow diagram of study selection process.

<p>Flow diagram of study selection process.</p